The international normalized ratio (INR) as seen in a population of patients with atrial fibrillation and cerebral infarction undergoing long-term treatment with vitamin K antagonists

1. Bamford J, at al.: Classif ication and natural history of clinically identifiable subtypes of cerebral infarction. Lancet, 337,1521-1526,1993.10.1016/0140-6736(91)93206-OSearch in Google Scholar

2. Conolly SJ.: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation, 118, 2029-2037, 2008.10.1161/CIRCULATIONAHA.107.75000018955670Search in Google Scholar

3. Crystal E, Connolly SJ: Role of oral anticoagulation in management of atrial fibrillation. Heart 20,813-817, 2004.10.1136/hrt.2003.021642176834115201261Search in Google Scholar

4. Garcia DA, Hylek EM.: Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med, 22, 155-156, 2006.10.1016/j.cger.2005.09.01116377472Search in Google Scholar

5. Hart RG, at al.: Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cedrebrovasc Dis, 10, 39-43, 2000.10.1159/00001602310629345Search in Google Scholar

6. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis. Ann Intern Med, 131,492-501, 1999.10.7326/0003-4819-131-7-199910050-0000310507957Search in Google Scholar

7. Hart RG, Halperin JL: Atrial fibrillation and stroke: concepts and controversies. Stroke 32, 803-808 , 2001.10.1161/01.STR.32.3.80311239205Search in Google Scholar

8. Hayek E, Griffin B: Mitral valve prolapse: old beliefs yield to new knowledge. Cleve Clin J Med.69:889-896,2002.10.3949/ccjm.69.11.88912430974Search in Google Scholar

9. Kernan WN, at al.: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160-2236, 2014.10.1161/STR.000000000000002424788967Search in Google Scholar

10. Kim YD, at al.: Factors associated with ischemic stroke on therapeutic anticoagulation in patients with nonvalvular atrial fibrillation. Yonsei Med J, 56, 410-417, 2015.10.3349/ymj.2015.56.2.410432935225683989Search in Google Scholar

11. Kohsaka S, at al.: Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging. 1, 617-623, 2008.10.1016/j.jcmg.2008.07.006284735819356491Search in Google Scholar

12. Lip GY, at al.: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the EuroHeart Survey on Atrial Fibrillation. Chest, 137, 263-272, 2010.10.1378/chest.09-158419762550Search in Google Scholar

13. Lip GY, at al.: ABC of atrial fibrillation. Aethiology, pathophysiology and clinical features. BMI 311,1425-1428,1995.10.1136/bmj.311.7017.142525443818520281Search in Google Scholar

14. Pujol Leris W, at al.: Ischemic stroke in patients with atrial fibrillation receiving oral anticoagulation. J Neurol Sci, 334, 139-142, 2013.10.1016/j.jns.2013.08.01324054537Search in Google Scholar

15. Stramba-Badiale M.: Atriall fibrillation subtypes, risk of stroke, and antithrombotic therapy. Eur Heart J 29, 840-842, 2008.10.1093/eurheartj/ehm59418334477Search in Google Scholar

16. Whitlock R, at al.: Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest, 141:576-600, 2012.Search in Google Scholar